Methamphetamine for HIV

(EMRLHD Trial)

This trial explores how short-term exposure to methamphetamine affects individuals with HIV who are effectively managing the virus with antiretroviral therapy. Researchers aim to determine if methamphetamine alters the remaining viral load, influences gene activity, or causes inflammation. Participants must be HIV-positive, have maintained consistent HIV treatment for at least a year, and have no history of methamphetamine use disorder. The goal is to discover new strategies to target HIV in those who might use methamphetamine, ultimately aiding in the fight against the virus. As a Phase 4 trial, this research examines an FDA-approved treatment to assess its benefits for a broader patient population, offering participants the opportunity to contribute to significant insights.

The trial does not specify that you need to stop taking your current medications, but you must not change your antiretroviral therapy (ART) during the study. Additionally, you cannot use certain medications like amphetamine-type stimulants or specific drugs that might interact with methamphetamine.

Research has shown that methamphetamine (MA) use can cause health problems for people living with HIV (PLWH). Studies indicate that methamphetamine use can make controlling the HIV virus more difficult, leading to worse health outcomes and more missed doses of HIV medication, complicating HIV management.

The trial you might join is in a later stage, indicating that substantial information about the treatment's safety already exists. While methamphetamine carries known risks, particularly concerning addiction and health effects, the trial is designed to closely monitor and manage these risks. Researchers carefully select and monitor participants to ensure their safety.

Unlike the standard treatments for HIV, which typically involve antiretroviral therapy (ART) to manage the virus, this trial is exploring the use of methamphetamine as a potential treatment. Researchers are curious about methamphetamine because it offers a completely different approach, targeting the brain's neurotransmitter systems rather than directly acting on the virus itself. This trial is particularly intriguing because it could uncover new insights into how methamphetamine might influence HIV progression or symptoms, potentially leading to novel therapeutic pathways.

This trial will explore the effects of methamphetamine on individuals with HIV. Research has shown that methamphetamine use leads to worse health outcomes for people with HIV. Studies have found that methamphetamine reduces the effectiveness of HIV treatments, making virus control more difficult. Users of this drug often miss more medical appointments and have a lower chance of managing the virus effectively. Methamphetamine also causes the immune system to become overactive and exhausted, weakening its ability to fight infections. Overall, while methamphetamine might be used in some research settings, its general use is linked to negative effects on managing HIV.¹⁴⁶⁷⁸